Blog
Latest articles, insights, and updates from the blog.
Contact Ketamine Resource
Send corrections, partnership questions, or advertising inquiries.
Ketamine vs. Esketamine: Side Effects and Who Stops Treatment
New clinical guidance on NMDA antagonist side effects and dropout rates helps patients make smarter choices about ketamine-based depression treatment.
Ketamine Side Effects: What the Data Says in 2026
New clinical guidance on NMDA antagonist side effects and dropout rates helps patients and providers make smarter decisions about ketamine treatment.
Faster TRD Remission: What Measurement-Based Care Means
New guidance on treatment-resistant depression emphasizes faster dose adjustment and symptom tracking—here's why it matters for ketamine patients.
Smarter TRD Care Gets Patients to Remission Faster
New psychiatric guidance on TRD highlights how symptom tracking and dose adjustment speed remission—here's what it means for ketamine patients.
Ketamine for TRD Works Better When Clinics Measure It
New research highlights how symptom tracking and dose optimization help treatment-resistant depression patients reach remission faster with ketamine.
Beyond 'Less Bad': Rethinking Treatment-Resistant Depression
New clinical thinking on treatment-resistant depression urges aggressive care aimed at full remission — not just symptom reduction. Here's what it means for patients.
Faster TRD Remission: What Better Protocols Mean for You
New guidance on TRD treatment highlights faster dose adjustment and symptom tracking. Here's what it means for patients considering ketamine.
Getting TRD Patients to Remission Faster in 2026
New analysis in Psychiatric Times shows measurement-based care and rapid dose adjustment get TRD patients to remission faster — here's what that means for ketamine.
How Active Clinical Management Speeds Up TRD Recovery
New analysis shows faster symptom tracking and dose adjustments lead to quicker TRD remission—here's what that means for ketamine therapy.
BPL-003 Shows Lasting Relief for Treatment-Resistant Depression
New phase 2a results for BPL-003 show sustained symptom reduction in treatment-resistant depression. What this means for ketamine patients.
A Chicago Fund Is Bridging Ketamine's Coverage Gap
A Chicago nonprofit is stepping in where insurers won't, covering ketamine treatment costs for patients with depression who can't afford to wait.
A Chicago Fund Is Closing Ketamine's Access Gap
A Chicago nonprofit is stepping in where insurers won't, funding ketamine treatment for depression patients who can't afford out-of-pocket costs.